扁蓄苷

Avicularin

	产品编号	CFN98961
	CAS编号	572-30-5
	分子式 = 分子量	C₂₀H₁₈O₁₁ = 434.4
	产品纯度	>=98%
	物理属性	Yellow powder
	化合物类型	Flavonoids
	植物来源	The herbs of Polygonum aviculare.
ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用

提供自定义包装

产品名称	产品编号	CAS编号	包装	QQ客服
扁蓄苷	CFN98961	572-30-5	10mg	QQ客服：2056216494
扁蓄苷	CFN98961	572-30-5	20mg	QQ客服：2056216494
扁蓄苷	CFN98961	572-30-5	50mg	QQ客服：2056216494
扁蓄苷	CFN98961	572-30-5	100mg	QQ客服：2056216494

存储与注意事项

1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。通常，这些可用于长达两周。使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

3. 需要更多关于溶解度，使用和处理的建议？请发送电子邮件至：service@chemfaces.com

订购流程

1. 在线订购

请联系我们QQ客服

2. 电话订购

请拨打电话：
027-84237683 或 027-84237783

3. 邮件或传真订购

发送电子邮件到: manager@chemfaces.com 或
发送传真到：027-84254680

提供订购信息

为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。

1. 产品编号（CAS No.或产品名称）

2. 发货地址

3. 联系方法 (联系人，电话）

4. 开票抬头 (如果需要发票的客户）

5. 发票地址（发货地址与发票地址不同）

发货时间

1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。

Description:

Avicularin exhibits anti-inflammatory activity through the suppression of ERK signaling pathway in LPS-stimulated RAW 264.7 macrophage cells; it inhibits the accumulation of the intracellular lipids by decreasing C/EBPα-activated GLUT4-mediated glucose uptake in adipocytes and potently inhibiting fatty acid synthase.

Targets:

GLUT | NO | PGE | NOS | COX | NF-kB | IkB | ERK | IL Receptor | IKK

In vitro:

Biomol Ther (Seoul). 2012 Nov;20(6):532-7.

Avicularin Inhibits Lipopolysaccharide-Induced Inflammatory Response by Suppressing ERK Phosphorylation in RAW 264.7 Macrophages.[Pubmed: 24009846]

suppresAvicularin, quercetin-3-α-L-arabinofuranoside, has been reported to possess diverse pharmacological properties such as anti-inflammatory and anti-infectious effects. However, the underlying mechanism by which avicularin exerts its anti-inflammatory activity has not been clearly demonstrated. This study aimed to elucidate the anti-inflammatory mechanism of avicularin in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophage cells.
METHODS AND RESULTS:
Avicularin significantly inhibited LPS-induced excessive production of pro-inflammatory mediators such as nitric oxide (NO) and PGE2 and the protein levels of iNOS and COX-2, which are responsible for the production of NO and PGE2, respectively. Avicularin also suppressed LPS-induced overproduction of pro-inflammatory cytokine IL-1β. Furthermore, avicularin significantly suppressed LPS-induced degradation of IκB, which retains NF-κB in the cytoplasm, consequently inhibiting the transcription of pro-inflammatory genes by NF-κB in the nucleus. To understand the underlying signaling mechanism of anti-inflammatory activity of avicularin, involvement of multiple kinases was examined. Avicularin significantly attenuated LPS-induced activation of ERK signaling pathway in a concentration-dependent manner.
CONCLUSIONS:
Taken together, the present study clearly demonstrates that avicularin exhibits anti-inflammatory activity through the suppression of ERK signaling pathway in LPS-stimulated RAW 264.7 macrophage cells.

Mol Med Rep . 2019 Jun;19(6):5417-5423.

Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF‑κB/COX‑2/PPAR‑γ activities[Pubmed: 31059053]

Abstract Hepatocellular carcinoma (HCC) has become a global public health problem. Therefore, the development of novel and effective therapeutic agents for the treatment of HCC is considered an emergency. Avicularin, a bio‑active flavonoid from plants, has been reported to exhibit diverse pharmacological properties. The aim of the present study was to investigate the role of avicularin in HCC and the underlying mechanism of action. Huh7 cells were treated with avicularin in a concentration‑dependent manner, and the cell proliferation was examined using a 3‑(4, 5‑dimethylthiazol‑2‑yl)‑2, 5‑diphenyltetrazolium bromide assay kit. The cell migration and invasion abilities were detected using wounding‑healing assays and Transwell assays. Flow cytometric analysis was performed to investigate the cell cycle distribution and cell apoptosis. The activity of nuclear factor (NF)‑κB (p65), cyclooxygenase‑2 (COX‑2) and peroxisome proliferator‑activated receptor γ (PPAR‑γ) were measured by reverse transcription‑quantitative polymerase chain reaction and western blot analyses, respectively. The results indicated that avicularin treatment markedly decreased cell proliferation concentration‑dependently in HCC, and inhibited cell migration and invasion in Huh7 cells. It was also found that the treatment of avicularin markedly inhibited the G0/G1‑phase cells and decreased the accumulation of S‑phase cells in the cell cycle and induced cell apoptosis. In addition, it was confirmed that the anticancer efficacy of avicularin in HCC was dependent on the regulation of NF‑κB (p65), COX‑2 and PPAR‑γ activities. In conclusion, the findings suggested that avicularin serves an antineoplastic role in HCC and may provide a potential therapeutic strategy for the treatment of

In vivo:

Planta Med. 2015 Mar;81(5):373-81.

Pharmacokinetic evaluation of avicularin using a model-based development approach.[Pubmed: 25782034]

The aim of this study was to use the pharmacokinetic information of avicularin in rats to project a dose for humans using allometric scaling.
METHODS AND RESULTS:
A highly sensitive and specific bioanalytical assay to determine avicularin concentrations in the plasma was developed and validated for UPLC-MS/MS. The plasma protein binding of avicularin in rat plasma determined by the ultrafiltration method was 64%. The pharmacokinetics of avicularin in nine rats was studied following an intravenous bolus administration of 1 mg/kg and was found to be best described by a two-compartment model using a nonlinear mixed effects modeling approach. The pharmacokinetic parameters were allometrically scaled by body weight and centered to the median rat weight of 0.23 kg, with the power coefficient fixed at 0.75 for clearance and 1 for volume parameters. Avicularin was rapidly eliminated from the systemic circulation within 1 h post-dose, and the avicularin pharmacokinetic was linear up to 5 mg/kg based on exposure comparison to literature data for a 5-mg/kg single dose in rats.
CONCLUSIONS:
Using allometric scaling and Monte Carlo simulation approaches, the rat doses of 1 and 5 mg/kg correspond to the human equivalent doses of 30 and 150 mg, respectively, to achieve comparable plasma avicularin concentrations in humans.

产品名称	产品编号	CAS编号	分子式 = 分子量	位单	联系QQ
槲皮素-3-O-beta-D-葡萄糖-7-O-beta-D-龙胆双糖苷; Quercetin 3-O-beta-D-glucose-7-O-beta-D-gentiobioside	CFN90920	60778-02-1	C₃₃H₄₀O₂₂ = 788.66	20mg	QQ客服：3257982914
槲皮素-3-O-β-D-吡喃葡糖基-7-O-[(2-O-反式芥子酰基)-β-D-吡喃葡糖基 (1→6)]-β-D-吡喃葡糖苷; Quercetin-3-O-beta-D-glucopyranosyl-7-O-[(2-O-trans-sinnapoyl)-beat-D-glucopyranosyl(1->6)]-beat-D-glucopyranoside)	CFN91832	N/A	C₄₄H₅₀O₂₆ = 994.9	5mg	QQ客服：3257982914
槲皮素 3,7-双葡萄糖苷; Quercetin 3,7-diglucoside	CFN95408	6892-74-6	C₂₇H₃₀O₁₇ = 626.5	10mg	QQ客服：1457312923
新化合物34; New compound 34	CFN95722	N/A	C₃₃H₄₀O₂₁ = 772.7	5mg	QQ客服：1457312923
新化合物35; New compound 35	CFN95744	N/A	C₃₉H₅₀O₂₆ = 934.8	5mg	QQ客服：3257982914
槲皮素-3-芸香糖苷-7-葡萄糖苷; Quercetin 3-rutinoside 7-glucoside (Morkotin A)	CFN70335	30311-61-6	C₃₃H₄₀O₂₁ = 772.7	10mg	QQ客服：3257982914
槲皮素3-O-刺槐糖苷-7-O-葡萄糖苷; Quercetin 3-O-robinoside-7-O-glucoside	CFN91650	115794-37-1	C₃₃H₄₀O₂₁ = 772.66	5mg	QQ客服：1457312923
槲皮素-3，7-二-O-β-D-龙胆双糖苷; Quercetin-3,7-di-O-beta-D-gentiobioside	CFN91831	N/A	C₃₉H₅₀O₂₇ = 950.8	5mg	QQ客服：1457312923
槲皮素-3'-葡萄糖苷; Quercetin-3'-glucoside	CFN95271	19254-30-9	C₂₁H₂₀O₁₂ = 464.4	10mg	QQ客服：2159513211
绣线菊苷; Spiraeoside	CFN70300	20229-56-5	C₂₁H₂₀O₁₂ = 464.4	5mg	QQ客服：1457312923

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.302 mL	11.5101 mL	23.0203 mL	46.0405 mL	57.5506 mL
5 mM	0.4604 mL	2.302 mL	4.6041 mL	9.2081 mL	11.5101 mL
10 mM	0.2302 mL	1.151 mL	2.302 mL	4.6041 mL	5.7551 mL
50 mM	0.046 mL	0.2302 mL	0.4604 mL	0.9208 mL	1.151 mL
100 mM	0.023 mL	0.1151 mL	0.2302 mL	0.4604 mL	0.5755 mL

扁蓄苷

Avicularin

信息支持

联系方式